Therapeutical neurotargeting via magnetic nanocarrier: Implications to opiate-induced neuropathogenesis and NeuroAIDS

Journal of Biomedical Nanotechnology

Volumn 11, Issue 10, 2015, Pages 1722-1733

  Sagar, Vidya ^a   Pilakka Kanthikeel, Sudheesh ^a   Atluri, Venkata S R ^a   Ding, Hong ^a   Arias, Adriana Y ^a   Jayant, Rahul D ^a   Kaushik, Ajeet ^a   Nair, Madhavan ^a  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

Blood Brain Barrier (BBB); HIV; Magnetic Nanoparticles; Morphine; Neuropathogenesis

Indexed keywords

BLOOD; CELL DEATH; DRUG PRODUCTS; ENZYME INHIBITION; FOURIER TRANSFORM INFRARED SPECTROSCOPY; HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY; MAGNETISM; MAGNETITE NANOPARTICLES; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; TRANSMISSION ELECTRON MICROSCOPY;

BLOOD-BRAIN BARRIER; HIV; MAGNETIC NANO-PARTICLES; MORPHINE; NEUROPATHOGENESIS;

NANOMAGNETICS;

DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLORNITHYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; MAGNETIC NANOPARTICLE; MORPHINE; NANOCARRIER; OPIATE; MAGNETITE NANOPARTICLE; NANOCAPSULE; PHENYLALANYL-CYCLO(CYSTEINYLTYROSYL-TRYPTOPHYL-ORNITHYL-THREONYL-PENICILLAMINE)THREONINAMIDE; SOMATOSTATIN;

APOPTOSIS; ARTICLE; ASSAY; BLOOD BRAIN BARRIER; BRAIN; CONFOCAL MICROSCOPY; DENDRITE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INFRARED SPECTROSCOPY; MORPHINE ADDICTION; MORPHOLOGY; NANOMEDICINE; NEUROPATHOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; TRANSMISSION ELECTRON MICROSCOPY; AIDS DEMENTIA COMPLEX; ANALOGS AND DERIVATIVES; CELL LINE; CHEMISTRY; DIFFUSION; DRUG EFFECTS; DRUG INTERACTION; MATERIALS TESTING; NERVE CELL; PATHOLOGY; TREATMENT OUTCOME; ULTRASTRUCTURE;

AIDS DEMENTIA COMPLEX; APOPTOSIS; CELL LINE; DIFFUSION; DRUG INTERACTIONS; HUMANS; MAGNETITE NANOPARTICLES; MATERIALS TESTING; NANOCAPSULES; NEURONS; OPIATE ALKALOIDS; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 84948666675     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2015.2108     Document Type: Article

References (57)

1. UNODC: World Drug Report (United Nations publication, Sales No. E.12.XI.1) (2012).
2. K. F. Hauser, N. El-Hage, A. Stiene-Martin, W. F. Maragos, A. Nath, Y. Persidsky, D. J. Volsky, and P. E. Knapp, HIV-1 neuropathogen-esis: Glial mechanisms revealed through substance abuse. J. Neu-rochem. 100, 567 (2007).
3. M. J. Ferris, C. F. Mactutus, and R. M. Booze, Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: Current status of dopamine system vulnerability in NeuroAIDS. Neuroscience and Biobehavioral Reviews 32, 883 (2008).
4. T. J. Rogers, Immunology as it pertains to drugs of abuse, AIDS and the neuroimmune axis: Mediators and traffic. Journal of Neuroim-mune Pharmacology 6, 20 (2011).
5. K. F. Hauser, N. El-Hage, S. Buch, J. R. Berger, W. R. Tyor, A. Nath, A. J. Bruce-Keller, and P. E. Knapp, Molecular targets of opiate drug abuse in neuro AIDS. Neurotoxicity Research 8, 63 (2005).
6. P. V. B. Reddy, S. Pilakka-Kanthikeel, S. K. Saxena, Z. Saiyed, and M. P. Nair, Interactive effects of morphine on HIV infection: Role in HIV-associated neurocognitive disorder. AIDS Research and Treatment Article ID 953678 (2012).
7. P. K. Peterson, T. W. Molitor, and C. C. Chao, The opioid-cytokine connection. Journal of Neuroimmunology 83, 63 (1998).
8. 2+, and the release of MCP-1, RANTES, and IL-6 by astrocytes treated with opiates and HIV-1 Tat. Glia 50, 91 (2005).
9. G. B. Stefano, B. Scharrer, E. M. Smith, T. K. Hughes Jr., H. I. Magazine, T. V. Bilfinger, A. R. Hartman, G. L. Fricchione, Y. Liu, and M. H. Makman, Opioid and opiate immunoregulatory processes. Critical Reviews™ in Immunology 16, 109 (1996).
10. V. Sagar, S. Pilakka-Kanthikeel, R. Pottathil, S. K. Saxena, and M. Nair, Towards nanomedicines for neuroAIDS. Reviews in Medical Virology 24, 103 (2014).
11. V. Sagar, S. Pilakka-Kanthikeel, H. Ding, V. S. R. Atluri, R. D. Jayant, A. Kaushik, and M. P. Nair, Novel magneto-electric nanode-livery of microRNA mimic across blood-brain barrier: Implicationsy to cocaine modulation on HIV-associated neurocognitive disorders. Journal of NeuroImmune Pharmacology 9, 49 (2014).
12. A. Kaushik, R. D. Jayant, V. Sagar, and M. Nair, The potential of magneto-electric nanoparticles for drug delivery. Expert Opinion on Drug Delivery 11, 1635 (2014).
13. S. Pilakka-Kanthikeel, V. S. R. Atluri, V. Sagar, and M. Nair, Targeted brain derived neurotropic factors (BDNF) delivery across the blood-brain barrier for neuro-protection using magnetic nano carriers: An in-vitro study. Plos One 8, e62241 (2013).
14. H. Ding, V. Sagar, M. Agudelo, S. Pilakka-Kanthikeel, V. S. R. Atluri, A. Raymond, T. Samikkannu, and M. P. Nair, Enhanced blood-brain barrier transmigration using a novel transferrin embedded fluorescent magneto-liposome nanoformulation. Nanotechnology 25, 055101 (2014).
15. M. Nair, R. Guduru, P. Liang, J. Hong, V. Sagar, and S. Khizroev, Externally controlled on-demand release of anti-HIV drug using magneto-electric nanoparticles as carriers. Nature communications 4, 1707 (2013).
16. N. Gandhi, Z. M. Saiyed, J. Napuri, T. Samikkannu, P. V. Reddy, M. Agudelo, P. Khatavkar, S. K. Saxena, and M. P. Nair, Interactive role of human immunodeficiency virus type 1 (HIV-1) clade-specific Tat protein and cocaine in blood-brain barrier dysfunction: implications for HIV-1-associated neurocognitive disorder. Journal of Neurovirology 16, 294 (2010).
17. V. S. R. Atluri, S. P. Kanthikeel, P. V. Reddy, A. Yndart, and M. P. Nair, Human synaptic plasticity gene expression profile and dendritic spine density changes in HIV-infected human CNS cells: Role in HIV-associated neurocognitive disorders (HAND). Plos One 8, e61399 (2013).
18. V. S. R. Atluri, S. Pilakka-Kanthikeel, S. Thangavel, V. Sagar, K. V. K. Rao, S. K. Saxena, A. Yndart, A. Raymond, H. Ding, O. Hernandez, and M. Nair, Vorinostat positively regulates synaptic plasticity genes expression and spine density in HIV infected neurons: Role of nicotine in progression of HIV-associated neurocognitive disorder. Molecular Brain 7, 37 (2014).
19. D. L. Smith, J. Pozueta, B. Gong, O. Arancio, and M. Shelanski, Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proc. Natl. Acad. Sci. USA 106, 16877 (2009).
20. K. R. V. Kurapati, V. S. R. Atluri, T. Samikkannu, and M. P. Nair, Ashwagandha (Withania somnifera) reverses-amyloid1-42 induced toxicity in human neuronal cells: Implications in HIV-associated neurocognitive disorders (HAND). Plos One 8, e77624 (2013).
21. C. Liu, Research and application of targeting nano-drugs. Nano Biomedicine and Engineering 3, 73 (2011).
22. E. Tombacz, A. Majzik, Z. Horvat, and E. Illes, Magnetite in aqueous medium: Coating its surface and surface coated with it. Romanian Reports in Physics 58, 281 (2006).
23. J.-W. Yoo, Toward improved selectivity of targeted delivery: The potential of magnetic nanoparticles. Arch. Pharmacal Res. 35, 1 (2012).
24. H. T. Iogo, M. Lim, V. Bulmus, L. A. Utirre, R. C. Oodward, and R. Amal, Insight into serum protein interactions with functional-ized magnetic nanoparticles in biological media. Langmuir 28, 4346 (2012).
25. N. Balaji, K. M. S. Begum, N. Anantharaman, and M. Uddin, Adsorption and desorption of L-Phenylalanine on nano-sized magnetic particles. Journal of Engineering and Applied Sciences 4, 39 (2006).
26. 4 magnetic nanofluid. Revista Latinoamericana de Metalurgia y Materiales 30, 60 (2010).
27. T. K. Eisenstein and M. E. Hilburger, Opioid modulation of immune responses: effects on phagocyte and lymphoid cell populations. Jour-nal of Neuroimmunology 83, 36 (1998).
28. D. Messmer, I. Hatsukari, N. Hitosugi, I. G. Schmidt-Wolf, and P. C. Singhal: Morphine reciprocally regulates IL-10 and IL-12 production by monocyte-derived human dendritic cells and enhances T cell activation. Molecular Medicine 12, 284 (2006).
29. V. Rivera-Amill, P. S. Silverstein, R. J. Noel Jr., S. Kumar, and A. Kumar, Morphine and rapid disease progression in nonhuman primate model of AIDS: Inverse correlation between disease progression and virus evolution. Journal of Neuroimmune Pharmacology 5, 122 (2010).
30. T. B. Saurer, K. A. Carrigan, S. G. Ijames, and D. T. Lysle, Suppression of natural killer cell activity by morphine is mediated by the nucleus accumbens shell. Journal of Neuroimmunology 173, 3
31. J. Wang, R. A. Barke, J. Ma, R. Charboneau, and S. Roy, Opiate abuse, innate immunity, and bacterial infectious diseases. Archivum Immunologiae et Therapiae Experimentalis 56, 299 (2008).
32. S. Thangavel, K. V. K. Rao, A. Y. Arias, A. Kalaicheian, V. Sagar, C. Yoo, and M. P. N. Nair, HIV Infection and drugs of abuse: Role of acute phase proteins. Journal of Neuroinflammation 10, 113 (2013).
33. M. Nair, R. Pottathil, E. Heimer, and S. Schwartz, Immunoregulatory activities of human immunodeficiency virus (HIV) proteins: Effect of HIV recombinant and synthetic peptides on immunoglobulin synthesis and proliferative responses by normal lymphocytes, Proceedings of the National Academy of Sciences 85, 6498 (1988).
34. F. Sarti, S. L. Borgland, V. N. Kharazia, and A. Bonci, Acute cocaine exposure alters spine density and long-term potentiation in the ventral tegmental area. European Journal of Neuroscience 26, 749 (2007).
35. M. Frankfurt, K. Salas-Ramirez, E. Friedman, and V. Luine, Cocaine alters dendritic spine density in cortical and subcortical brain regions of the postpartum and virgin female rat. Synapse 65, 955 (2011).
36. E. J. Nestler, Molecular basis of long-term plasticity underlying addiction. Nazure Reviews Neuroscience 2, 119 (2001).
37. Y. Li, H. Wang, L. Niu, and Y. Zhou, Chronic morphine exposure alters the dendritic morphology of pyramidal neurons in visual cortex of rats. Neuroscience Letters 418, 227 (2007).
38. T. E. Robinson and B. Kolb, Alterations in the morphology of dendrites and dendritic spines in the nucleus accumbens and prefrontal cortex following repeated treatment with amphetamine or cocaine. European Journal of Neuroscience 11, 1598 (1999).
39. S. D. Mahajan, S. A. Schwartz, T. C. Shanahan, R. P. Chawda, and M. P. Nair, Morphine regulates gene expression of a-and)3-chemokines and their receptors on astroglial cells via the opioid/x receptor. The Journal of Immunology 169, 3589 (2002).
40. R. Goswami, S. A. Dawson, and G. Dawson, Cyclic AMP protects against staurosporine and wortmannin-induced apoptosis and opioid-enhanced apoptosis in both embryonic and immortalized (F-11K7) neurons. J. Neurochem. 70, 1376 (1998).
41. D. Yin, R. A. Mufson, R. Wang, and Y. Shi, Fas-mediated cell death promoted by opioids. Nature 397, 218 (1999).
42. S. Hu, W. S. Sheng, J. R. Lokensgard, and P. K. Peterson, Morphine potentiates HIV-1 gp120-induced neuronal apoptosis. Journal of Infectious Diseases 191, 886 (2005).
43. M. L. Simonato, The neurochemistry of morphine addiction in the neocortex. Trends in Pharmacological Sciences 17, 410 (1996).
44. A. Nath, C. Anderson, M. Jones, W. Maragos, R. Booze, C. Mactutus, J. Bell, K. F. Hauser, and M. Mattson, Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. Journal of Psychopharmacology 14, 222 (2000).
45. A. Nath, K. F. Hauser, V. Wojna, R. M. Booze, W. Maragos, M. Prendergast, W. Cass, and J. T. Turchan, Molecular basis for interactions of HIV and drugs of abuse. Journal of Acquired Immune Deficiency Syndromes (1999) 31, S62-9 (2002).
46. P. K. Peterson, G. Gekker, S. Hu, W. R. Anderson, F. Kravitz, P. S. Portoghese, H. H. Balfour Jr., and C. C. Chao, Morphine amplifies HIV-1 expression in chronically infected promonocytes cocultured with human brain cells. Journal of Neuroimmunology 50, 167 (1994).
47. M. Rojavin, I. Szabo, J. L. Bussiere, T. J. Rogers, M. W. Adler, and T. K. Eisenstein, Morphine treatment in vitro or in vivo decreases phagocytic functions of murine macrophages. Life Sci. 53, 997 (1993).
48. N. Zhang and J. J. Oppenheim, Crosstalk between chemokines and neuronal receptors bridges immune and nervous systems. Journal of Leukocyte Biology 78, 1210 (2005).
49. J. A. Beltran, A. Pallur, and S. L. Chang, HIV-1 gp120 up-regulation of the mu opioid receptor in TPA-differentiated HL-60 cells. International Immunopharmacology 6, 1459 (2006).
50. J. Moorman, Y. Zhang, B. Liu, G. LeSage, Y. Chen, C. Stuart, D. Prayther, and D. Yin, HIV-1 gp120 primes lymphocytes for opioid-induced,/3-arrestin 2-dependent apoptosis. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1793, 1366 (2009).
51. T. K. Jain, M. K. Reddy, M. A. Morales, D. L. Leslie-Pelecky, and V. Labhasetwar, Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats. Molecular Pharmaceutics 5, 316 (2008).
52. S. Choi, A. Tripathi, and D. Singh, Smart nanomaterials for biomedics. J. Biomed. Nanotechnol. 10, 3162 (2014).
53. A. M. Pekkanen, M. R. DeWitt, and M. N. Rylander, Nanoparticle enhanced optical imaging and phototherapy of cancer. J. Biomed. Nanotechnol. 10, 1677 (2014).
54. L. Zhang and D. Zhao, Applications of nanoparticles for brain cancer imaging and therapy. J. Biomed. Nanotechnol. 10, 1677 (2014).
55. R. D. Jayant and R. Srivastava, Dexamethasone release from uniform sized nanoengineered alginate microspheres. Journal of Biomedical Nanotechnology 3, 1 (2007).
56. A. Ahsan, A. Aziz, M. A. Arshad, O. Ali, M. Nauman, N. M. Ahmad, and A. Elaissari, Smart magnetically engineering colloids and biothin films for diagnostics applications. J. Colloid Sci. Biotech-nol. 2, 19 (2013).
57. Z. Roveimiab, A. R. Mahdavian, E. Biazar, and K. S. Heidari, Preparation of magnetic chitosan nanocomposite particles and their susceptibility for cellular separation applications. J. Colloid Sci. Biotechnol. 1, 82 (2012).